SGN-CD33A

About Vadastuximab Talirine (SGN-CD33A; 33A)

SGN-CD33A is a novel antibody-drug conjugate (ADC) targeting CD33, which is expressed on most acute myeloid leukemia (AML) cells. 33A utilizes our newest ADC technology comprising a highly potent DNA binding agent, a pyrrolobenzodiazepine (PBD) dimer, attached via a proprietary site-specific conjugation technology to a monoclonal antibody with engineered cysteines (EC-mAb). PBD dimers are significantly more potent than systemic chemotherapeutic drugs and the site-specific conjugation technology allows uniform drug-loading of the cell-killing PBD agent to the anti-CD33 antibody. The ADC is designed to be stable in the bloodstream and to release its potent DNA binding agent upon internalization into CD33-expressing cells.

Status

33A is being evaluated in several ongoing and planned phase 1 and phase 1/2 clinical trials. A phase 3 clinical trial for newly diagnosed patients with AML is planned for 2016.

To learn more about 33a, including announcements and clinical trial info, visit www.ADC-CD33.com

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com